March 15, 2021 -- Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.
Takeda will make manufacturing capacity available at IDT's facilities in Germany and Japan. After three months, the capacity will be returned to Takeda to resume manufacturing for the planned launch of its dengue vaccine, TAK-003, subject to regulatory approvals.
Takeda previously announced that it is partnering with Novavax and Moderna to manufacture and distribute the authorized vaccines in Japan.